Symbiotec Pharmalab Limited
Issue Structure & OFS vs Fresh Capital Split
| Offering Parameter / Tranche | Allocation & Value | % of Gross Issue | Strategic Mandate / Terms |
|---|---|---|---|
| Fresh Issue (Primary Growth Capital) | ₹150.00 cr (aggregating up to ₹1,500.00 million). | 8.5% | Balance sheet equity expansion directly fueling capex, debt repayment & operations |
| Offer for Sale (OFS - Insiders) | ₹1,607.00 cr (aggregating up to ₹16,070.00 million). | 91.5% | Secondary liquidity realization for existing promoters & early institutional funds |
| Gross Total Issue Size | ₹1,757.00 Cr | 100.0% | Aggregate primary market capital raising at upper price band |
| Net Proceeds Reaching Company | Net Proceeds = ₹150.00 cr minus company's portion of offer expenses (~₹140-145 cr net). Company receives ₹0 from the ₹1,607 cr OFS. | - | Net growth funds after deducting book building issue & underwriting expenses |
| Anchor Investor Allocation Tranche | ₹527.10 Cr (30.0% of Issue) | Up to 30.0% | Reserved anchor allotment tranche for institutional Qualified Institutional Buyers (QIBs) |
| Pre-IPO WACA Benchmark | WACA of selling shareholders: Satwani Holdings LLP ₹49.43 (Offer price ₹988 is 20.0x WACA); Rosewood Investments ₹147.21 (6.71x WACA); India Business Excellence Fund-III ₹147.21 (6.71x WACA). | Weighted average cost of acquisition for promoters & early funds | |
| Selling Shareholders & Dilution | Selling Shareholders: Rosewood Investments (up to ₹988 cr), India Business Excellence Fund-III (up to ₹475 cr), and Satwani Holdings LLP (Promoter, up to ₹144 cr). PE exit + promoter monetization. | ||
| Intermediary / Regulatory Entity | Entity Name / Details | Statutory Function & Status |
|---|---|---|
| Book Running Lead Managers (BRLMs) | SEBI Registered Merchant Bankers / BRLMs | Issue pricing, underwriting, book building & institutional roadshows |
| Registrar to the Issue | SEBI Category-I Registrar | Allotment finalization, Demat share transfer & ASBA refund processing |
| Proposed Listing Exchanges | NSE / BSE | Trading segments, ticker assignment & continuous disclosure compliance |
| Regulatory Prospectus Stage | DRHP / RHP Filed | SEBI ICDR compliance review & exchange in-principle listing approval |
Revenue Breakdown, Product Mix & Customer Concentration
| Product / Operating Segment | Share (%) | Value / Channel |
|---|---|---|
Corticosteroid & Hormone APIs | ₹835.01 Cr | |
Complex Sterile Injectables | ₹33.05 Cr | |
CDMO & Custom Synthesis Services | ₹1.09 Cr |
| Market Segment / Customer Concentration Tier | Share (%) | Reported Value | Concentration & Risk Profile |
|---|---|---|---|
| Corticosteroid & Hormone APIs | 96.1% | ₹835.01 Cr | Global specialty API formulations |
| Complex Sterile Injectables & Formulation CDMO | 3.9% | ₹34.14 Cr | USFDA-compliant injectables |
| International Export Sales (Europe, USA, RoW) | 67.0% | ₹582.64 Cr | Export presence in 60+ countries |
| Domestic India Sales | 33.0% | ₹286.51 Cr | Domestic pharma formulations OEMs |
| Top 1 Customer | 16.1% | ₹130.34 Cr | Multinational generic pharma major |
| Top 5 Customers | 43.0% | ₹347.60 Cr | Tier-1 pharmaceutical customers |
Capital Allocation (Where the Fresh Money Goes)
| Object of the Offer / Proposed Expenditure | Amount (₹ Cr) | % of Fresh Issue | Deployment Timeline / Purpose |
|---|---|---|---|
| Debt Deleveraging (Prepayment of borrowings) | ₹112.50 Cr | 75.0% | Scheduled term loan reduction |
| General Corporate Purposes (GCP) | ₹37.50 Cr | 25.0% | Working capital & ops |
| Total Fresh Growth Capital | ₹150.00 Cr | 100.0% | Balance Sheet Inflow |
3-Year Audited Financial Health & Margins
| Audited Metric / Line Item | FY24 | FY25 | FY26 | 3-Yr CAGR |
|---|---|---|---|---|
| Revenue from Operations | ₹716.25 Cr | ₹751.55 Cr | ₹869.15 Cr | +10.2% |
| EBITDA (Operating Profit) | ₹177.04 Cr (24.5%) | ₹206.11 Cr (27.3%) | ₹231.97 Cr (26.6%) | +14.5% |
| Profit After Tax (PAT) | ₹100.06 Cr (13.8%) | ₹96.79 Cr (12.8%) | ₹109.90 Cr (12.6%) | +4.8% |
| Operating Cash Flow (CFO) | ₹187.50 Cr | ₹47.26 Cr | ₹174.59 Cr | Strong CFO |
| Adjusted ROCE (ex-CWIP) | 24.59% | 27.71% | 30.43% | 30%+ Adj |
| Debt-to-Equity (D/E) | 0.35x | 0.66x | 0.34x | Conservative |
Governance, Lock-in & Litigation Review
| Shareholder Category / Promoter Group | Pre-IPO Holding (%) | Post-IPO Holding (%) | Mandatory Lock-in Terms & Dilution |
|---|---|---|---|
| Promoters (Anil Satwani & Family) | 65.21% | 34.00% | 20% locked for 18 Mos; balance 6 Mos |
| Private Equity Investors (Rosewood / Actis) | 32.80% | 8.50% | Secondary OFS exit |
| Public & Institutional Float | 1.99% | 57.50% | Fresh + 75% OFS float |
| Litigation Category / Proceedings | Adjudicating Forum | Quantifiable Exposure | Materiality Assessment |
|---|---|---|---|
| Direct Tax Reassessment Appeals | ITAT | ₹50.79 Cr | Tax assessment orders contested in appeal |
| Competitor Defamation Suit | Commercial Court | ₹100.00 Cr | Defamation suit filed by third party |
| USFDA / Regulatory Inspections | USFDA / EU GMP | ₹0.00 Cr | Clean EIR / GMP compliance |
1. Executive Business Summary & Core Operations
Symbiotec Pharmalab combines genuine global leadership in corticosteroid APIs (38.2% volume share) with massive 700 KL fermentation scale and 63.7% gross margins. However, with 91.5% of the ₹1,757 cr issue being an OFS exit for PE investors at a demanding 52.0x P/E against modest historical 4.8% PAT CAGR, my stance is neutral with a preference to track execution post-listing.
2. Value Proposition, Products & Operations
Symbiotec is a specialized biotechnology and pharmaceutical manufacturer focused on complex corticosteroid and steroidal-hormone APIs, complex sterile injectables, and CDMO services. It operates a vertically integrated 'microbe-to-pharmacy' platform spanning multi-step chemical synthesis (up to 400 steps) and industrial-scale fermentation across four facilities in Madhya Pradesh.
3. Industry Dynamics & Market Positioning
The Offer totals ₹1,757.00 cr, consisting of a small ₹150.00 cr Fresh Issue (8.5%) and a large ₹1,607.00 cr Offer for Sale (91.5%). Private equity funds Rosewood Investments (₹988 cr) and Motilal Oswal PE / IBEF-III (₹475 cr) are cashing out at 6.71x their WACA, while promoter entity Satwani Holdings sells ₹144 cr at 20.0x WACA. Fresh proceeds are strictly used for debt prepayment (₹112.50 cr) and general corporate purposes.
4. Detailed Financial Trajectory & Margin Analysis
Financial quality is solid on operating cash conversion: FY26 CFO stood at ₹174.59 cr (1.59x PAT), with cumulative 3-year CFO/PAT at 1.33x. Gross margins expanded from 55.2% in FY24 to 63.7% in FY26 as in-house fermentation replaced imported intermediates. Negative 3-year FCF (-₹334 cr) reflects genuine heavy capital expenditure on Ujjain and Mhow facilities (over ₹740 cr spent) rather than poor earnings quality.
5. Promoter Integrity, Governance & Shareholding
Anil Satwani has led the business for over 30 years with zero promoter share pledge. The board is structurally sound with 62.5% independent directors (5 of 8) and reputable statutory auditor S R B C & CO LLP (EY). Consolidated RPTs are strictly confined to managerial remuneration (~₹11.58 cr to promoter family = 10.5% of PAT) with zero outside related party trading. Minor past non-compliance regarding company secretary appointment (2005-2014) is pending compounding before NCLT.
6. Relative Valuation & Benchmark Multiples
| Company Name | CMP / Issue Price (₹) | P/E Ratio (x) | EV / EBITDA (x) | RoNW / ROCE (%) | Annual Revenue (₹ Cr) |
|---|---|---|---|---|---|
| Symbiotec Pharmalab Limited | ₹988 | 32.4x | 18.5x | 30.4% | ₹869.15 Cr |
| Divi's Laboratories Limited | ₹5,400 | 78.5x | 48.2x | 21.4% | ₹7,840.00 Cr |
| Supriya Lifescience Limited | ₹520 | 31.8x | 18.2x | 22.8% | ₹590.00 Cr |
| Aarti Drugs Limited | ₹480 | 24.2x | 13.5x | 14.5% | ₹2,710.00 Cr |
| API Peer Composite | - | 44.8x | 26.6x | 19.6% | - |
At the fixed Offer Price of ₹988, Symbiotec is valued at a post-issue market cap of ₹6,348.20 cr, translating to a Diluted P/E of 52.00x, EV/EBITDA of 29.01x, and P/B of 5.35x on FY26 financials. While this is a discount to rich large-cap peer multiples (peer average 88.3x, Concord 61.1x, Divi's 87.8x), it is rich relative to Symbiotec's 3-year PAT CAGR of 4.80% and unadjusted ROCE of 11.56%.